ContributorsPublishersAdvertisers

Dr. Raghav on the Rationale for the DESTINY-CRC02 Trial in HER2+ mCRC

onclive.com
 2022-01-21

Kanwal P.S. Raghav, MBBS, MD, discusses the rationale for the ongoing phase 2 DESTINY-CRC02 trial in HER2-overexpressing metastatic colorectal cancer. Kanwal P.S. Raghav, MBBS, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, medical director, Division of Ambulatory Treatment Centers, The University of Texas MD...

www.onclive.com

Comments / 0

Comments / 0